drugset / Trial / NCT01049854
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Non-randomizedParallel-groupOpen-labelTreatment
Summary
CD34+ stem cell selection in children, adolescents and young adults receiving partially matched family donor or matched unrelated adult donor allogeneic bone marrow or peripheral blood stem cell transplant will be safe and well tolerated and be associated with a low incidence of serious (Grade III/IV) acute and chronic graft versus host disease (GVHD).
Timeline
- Start
- 2011-09
- Primary completion
- 2017-11
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | — | — |
| Subject | Busulfan | Small molecule | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Fludarabine | Small molecule | — | — |
| Subject | Melphalan | Small molecule | — | — |
| Subject | Thiotepa | Other / unclassified | — | — |
| Subject | antithymocyte globulin (horse) | Protein / enzyme biologic | — | — |
| Subject | rabbit anti-thymocyte globulin | Protein / enzyme biologic | — | — |
| Background | GM-CSF | Protein / enzyme biologic | — | — |
| Background | Tacrolimus | Small molecule | — | — |